// App-Quantinova.ai

BSH2020‐PO‐049 : A clinical audit on compliance with British Society of Haematology guidelines for diagnosis and management of Philadelphia negative myeloproliferative neoplasms

Researchers

Presenter

  • F. Karim

Principal Investigators

  • E. Mazhar

Medical Centers

  • Clinical Haematology, Royal Wolverhampton NHS trust, Wolverhampton, UK

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

  • Oncology (ONC)

Disease

  • Myeloid neoplasms

  • Essential thrombocythemia

  • Polycythemia vera

  • Myelofibrosis

  • Venous thrombosis

Biomarkers

  • Abelson murine leukemia viral oncogene homolog

  • MPL proto-oncogene, thrombopoietin receptor

  • Breakpoint Cluster Region

  • Calreticulin

  • Ph chromosome

  • Janus kinase

Drug/Treatment

  • Hydroxycarbamide

  • SJ8903

  • Ruxolitinib phosphate

  • Anagrelide hydrochloride

  • Busulfex

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved